SGLT-2i patients had an equivalent threat of myocardial infarction, stroke, and all-cause death, but a reduced danger of cardiac arrest hospitalization compared to clients taking metformin.
A new kind of 2 diabetes drug reduced the opportunity of cardiac arrest hospitalization.
Sodium-glucose co-transporter 2 inhibitors (SGLT-2i) have revealed healing potential in cardiovascular result research studies among individuals with type 2 diabetes (T2D), consisting of a lower threat of hospitalization for heart failure when compared to placebo.
SGLT-2i have actually mostly been studied as a second-line medication– metformin is typically used as a first-line diabetes treatment.
In a recent research study, Brigham researchers assessed cardiovascular outcomes amongst patients with T2D who started first-line treatment with metformin or SGLT-2i. In the trial, 8,613 SGLT-2i patients were matched to 17,226 metformin clients.
When compared to metformin, individuals taking SGLT-2i had a comparable threat of myocardial infarction, stroke, and all-cause death, but a decreased threat of hospitalization for cardiac arrest. The threat of adverse occasions was comparable, with the exception of an increased danger of genital infections when compared to those taking metformin.
” Our results suggest that SGLT-2i may be thought about as first-line treatment for patients with T2D and heart disease or who are at increased danger for cardiovascular events,” stated lead author HoJin Shin, BPharm, Ph.D., of the Division of Pharmacoepidemiology and Pharmacoeconomics.
” However, more evidence from randomized clinical trials or observational studies will assist us to recognize patients who would benefit most from using SGLT-2i as first-line type 2 diabetes treatment.”
Recommendation: “Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin” by HoJin Shin, BPharm, Ph.D., Sebastian Schneeweiss, MD, ScD, Robert J. Glynn, ScD, Ph.D. and Elisabetta Patorno, MD, DrPH, 24 May 2022, Annals of Internal Medicine.DOI: 10.7326/ M21-4012.
The research study was moneyed by the Division of Pharmacoepidemiology and Pharmacoeconomics, the Department of Medicine, Brigham and Womens Hospital, Harvard Medical School, NIH/National Institute on Aging, and Patient-Centered Outcomes Research Institute..
